ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, IMMvention Collaboration
ScripVertex Pharmaceuticals’ Journavx (suzetrigine) has gained US Food and Drug Administration approval for acute pain, but the question now is how well it might fare commercially, with analysts forecastin
ScripVertex Pharmaceuticals is looking to replicate the successful franchise model it created in cystic fibrosis with CFTR modulators in a new therapeutics area – pain, where it has spent 25 years advancin